白塞综合征临床表型分类和研究进展
收稿日期: 2022-02-09
网络出版日期: 2022-08-09
基金资助
国家自然科学基金项目(81871276);上海申康医院发展中心临床科技创新项目(SHDC12017129)
邹峻, 管剑龙 . 白塞综合征临床表型分类和研究进展[J]. 内科理论与实践, 2022 , 17(03) : 195 -197 . DOI: 10.16138/j.1673-6087.2022.03.004
| [1] | Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome[J]. Ann Rheum Dis, 2018, 77(6): 808-818. |
| [2] | Bettiol A, Hatemi G, Vannozzi L, et al. Treating the different phenotypes of Behçet’s syndrome[J]. Front Immunol, 2019, 10: 2830. |
| [3] | 邹峻, 陈永, 曲环汝, 等. 中国白塞综合征中西医结合诊疗专家共识(2020年)[J]. 老年医学与保健, 2021, 27(1): 14-20. |
| [4] | Hou CC, Ye JF, Ma HF, et al. Clinical characteristics and risk factors of intestinal involvement in Behçet’s syndrome patients: a cross-sectional study from a single center[J]. Orphanet J Rare Dis, 2021, 16(1): 132. |
| [5] | Chen Y, Cai JF, Lin CH, et al. Demography of vascular Behçet’s disease with different gender and age: an investigation with 166 Chinese patients[J]. Orphanet J Rare Dis, 2019, 14(1): 88. |
| [6] | 鲍华芳, 蔡剑飞, 陈永, 等. STAT3磷酸化与白塞病临床活动性的关系[J]. 复旦学报(医学版), 2018, 45(2):169-176. |
| [7] | Shen Y, Ma HF, Luo D, et al. High incidence of gastrointestinal ulceration and cytogenetic aberration of trisomy 8 as typical features of Behçet’s disease associated with myelodysplastic syndrome[J]. Biomed Res Int, 2018, 2018: 8535091. |
| [8] | Zou J, Luo JF, Shen Y, et al. Cluster analysis of phenotypes of patients with Behçet’s syndrome: a large cohort study from a referral center in China[J]. Arthritis Res Ther, 2021, 23(1): 45. |
| [9] | McHugh J. Different phenotypes identified for Behçet syndrome[J]. Nat Rev Rheumatol, 2021, 17(4): 188. |
| [10] | Zou J, Luo JF, Shen Y, et al. Distinct clinical characteristics of pediatric Behçet’s syndrome: a study from a referral center in China[J]. Mod Rheumatol, 2021, 31(6): 31(6):1158-1163. |
| [11] | Zou J, Luo D, Shen Y, et al. Characteristics and phenotype heterogeneity in late-onset Behçet’s syndrome: a cohort from a referral center in China[J]. Clin Rheumatol, 2021, 40(6): 2319-2326. |
| [12] | Ye JF, Hou CC, Bao HF, et al. New insight into the features of Behçet’s disease with gastrointestinal ulcer[J]. Orphanet J Rare Dis, 2021, 16(1): 444. |
| [13] | Ye JF, Guan JL. Differentiation between intestinal Behçet’s disease and Crohn’s disease based on endoscopy[J]. Turk J Med Sci, 2019, 49(1): 42-49. |
| [14] | Zhang L, Tian Y, Ye JF, et al. Poor prognostic factors in patients with newly diagnosed intestinal Adamantiades-Behçet’s disease in the Shanghai Adamantiades-Behçet’s disease database[J]. Orphanet J Rare Dis, 2019, 14(1): 274. |
| [15] | Bao HF, Hou CC, Ye B, et al. Predictors of infliximab refractory intestinal Behçet’s syndrome: a retrospective cohort study from the Shanghai Behçet’s syndrome database[J]. Mod Rheumatol, 2021. [Epub ahead of print]. |
| [16] | Hou CC, Ma HF, Ye JF, et al. Plasma exosomes derived from patients with intestinal Behçet’s syndrome induce intestinal epithelial cell pyroptosis[J]. Clin Rheumatol, 2021, 40(10):4143-4155. |
| [17] | Hou CC, Bao HF, Shen Y, et al. Expression of miRNAs derived from plasma exosomes in patients with intestinal Behçet’s syndrome[J]. Clin Exp Rheumatol, 2021. [Epub ahead of print]. |
| [18] | Zou J, Lin CH, Wang Y, et al. Correspondence on ‘A pilot study of tofacitinib for refractory Behçet’s syndrome’[J]. Ann Rheum Dis, 2021. [Epub ahead of print]. |
| [19] | 管剑龙,主编. 白塞病新概念[M]. 上海: 复旦大学出版社, 2021:55-91. |
/
| 〈 |
|
〉 |
